I'm not recruiting for Astrazeneca, but news broke this morning that they are to start phase 3 clinical trials of a long-acting antibody combination AZD7442. This will be aimed at helping clinically vulnerable groups, including immunosuppressed, for whom the COVID vaccines may not be effective lbc.co.uk/news/uk-first-to-...
The trial will recruit 1,000 subjects in the UK, 5,000 globally. I'm going to ask my haematologist, consultation next Tuesday.
An earlier press release gives some background: astrazeneca.com/media-centr...